Ziltivekimab for plaque after a heart attack
Treatments studied
Part of Heart & circulation clinical trials.
This study tests a drug called ziltivekimab to see if it can reduce fatty plaque buildup in heart arteries after a heart attack. It's for people who had a heart attack treated with a stent and have mild blockages in other arteries.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a heart attack that was treated with a stent.
- You have at least two heart arteries with mild narrowing (20–50%) that haven't been stented before and can be looked at with a tiny camera.
- You are not pregnant and cannot become pregnant.
- You are not taking strong immune-suppressing medications (like methotrexate or biologics) and haven't had a serious infection in the past year.
- You don't have severe kidney or liver disease, active cancer, or other major health issues that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special heart and blood vessel imaging to see how two new medicines affect inflammation and healing after a heart attack. It is an early-stage trial that may help doctors improve recovery after a heart attack.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
This study looks at blood clotting (platelets) during the first phase after a heart attack. You may be able to join if you were recently diagnosed with a heart attack and received standard heart-attack blood thinners like aspirin and a second anti-platelet medicine.
This trial tests a new drug called Ziltivekimab to see if it can reduce plaque buildup in the heart arteries after a heart attack. It may help prevent future heart problems by targeting inflammation.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This study tests whether adding the drug rituximab to standard heart attack treatment can reduce damage to the heart muscle after a heart attack. Rituximab is usually used for immune system conditions, and it may help calm inflammation and protect the heart. Participants must have a certain type of heart attack and be treated quickly.
Hear when a new Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.